Clinical Trials on Recurrent Acute Myeloid Leukemia, Adult

Total 6403 results

Shanghai Pudong Hospital
UTC Therapeutics Inc.

Withdrawn

Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | B-cell Non-Hodgkin's Lymphoma (B-NHL) | T-Cell Leukemia/Lymphoma, Adult | B-cell Acute Lymphoblastic Leukemia (B-ALL)

China
University of Birmingham
Jazz Pharmaceuticals; Adienne SA; IMPACT (funded by NHS Blood & Transplant, Anthony...

Active, not recruiting

A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT (COSI)

Acute Myeloid Leukaemia | High-risk Myelodysplastic Syndrome

United Kingdom
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia and other conditions

United States
Shanghai Jiao Tong University School of Medicine

Terminated

ASCT for Relapsed APL After Molecular Remission

Acute Promyelocytic Leukemia | Relapse

China
Oryzon Genomics S.A.

Recruiting

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) (FRIDA)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
University Hospital, Antwerp

Recruiting

Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

Belgium
Medical College of Wisconsin

Recruiting

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS) | Acute Myeloid Leukaemia (AML)

United States, Australia, France, Spain
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent... and other conditions

United States
Ruijin Hospital

Not yet recruiting

The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Washington University School of Medicine

Withdrawn

Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid Leukemia

United States
C. Babis Andreadis
Gateway for Cancer Research; AVEO Pharmaceuticals, Inc.

Terminated

Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid Leukemia

United States
ECOG-ACRIN Cancer Research Group

Recruiting

Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Lymphoblasts 5 Percent or More of Bone Marrow Nucleated Cells

United States
M.D. Anderson Cancer Center

Recruiting

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Lymphoblastic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia | Refractory Lymphoblastic Lymphoma

United States
Juan C. Ramos, MD

Withdrawn

Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias

Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Refractory Leukemia | Adult T-Cell Leukemia/Lymphoma | Relapsed Leukemia

United States
Samara State Medical University

Recruiting

Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML

Endothelial Dysfunction | Cardiotoxicity | Acute Myeloid Leukemia, Adult

Russian Federation
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Completed

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myeloproliferative Neoplasm | Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells

United States
Wuhan Union Hospital, China

Recruiting

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Allogeneic Hematopoietic Stem Cell Transplantation | Acute Myeloid Leukemia, Adult | Myelodysplastic Syndrome(MDS)

China
German Cancer Research Center
University Hospital Heidelberg; University Hospital Dresden

Not yet recruiting

Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients With AML (GALAXY33)

Relapsed/Refractory Acute Myeloid Leukemia (AML)

Germany
Georgetown University
National Heart, Lung, and Blood Institute (NHLBI); Jazz Pharmaceuticals

Recruiting

Phase IB/II of CPX-351 for Relapse Prevention in AML

Acute Myeloid Leukemia (AML) in Remission

United States
Massachusetts General Hospital
Celgene Corporation

Terminated

Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML

Acute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States, Italy
Peking University People's Hospital
Beijing JD Biotech Co. LTD.

Recruiting

Off-the-shelf CD123 CAR-NK for R/R AML

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Xuzhou Medical University

Recruiting

Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Bio-Path Holdings, Inc.

Recruiting

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia

Childhood Acute Erythroleukemia (M6) | Childhood Acute Megakaryocytic Leukemia (M7) | Childhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia With Maturation (M2) | Childhood Acute Myeloblastic Leukemia Without Maturation... and other conditions

United States
Xuzhou Medical University

Recruiting

Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Genzyme, a Sanofi Company

Completed

A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML)

Acute Myelogenous Leukemia

Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

Hematopoietic and Lymphoid Cell Neoplasm | Myelofibrosis | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia | High Risk... and other conditions

United States
Seagen Inc.

Completed

A Safety Study of SGN-CD33A in AML Patients

Acute Myeloid Leukemia | Acute Myelogenous Leukemia | Acute Promyelocytic Leukemia

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML

Acute Myeloid Leukemia | Acute Myelogenous Leukemia | Acute Myeloid Leukemia With Maturation | Acute Myeloid Leukemia Without Maturation | ANLL

China
Cell Medica Ltd
University College, London; Cell Therapy Catapult

Completed

WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study

Acute Myeloid Leukaemia | Chronic Myeloid Leukaemia

United Kingdom
National Cancer Institute (NCI)

Not yet recruiting

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory High Risk Myelodysplastic Syndrome
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.; Union Stem cell & gene engineering Co.LTD

Completed

CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, Adult B-Cell | Acute Lymphoblastic Leukaemia Recurrent

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Newly Diagnosed Acute Myeloid Leukemia (AML)

China
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia Leukemia

China
Celgene

Completed

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myelogenous Leukemia

United States, Canada
Actinium Pharmaceuticals

Active, not recruiting

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA)

Acute Myeloid Leukemia | Leukemia, Myeloid, Acute | AML | Acute Myelogenous Leukemia | Bone Marrow Transplant | Myelogenous Leukemia, Acute | Myeloid Leukemia, Acute | Leukemia, Acute Myelogenous | Leukemia, Acute Myeloid

United States, Canada
Centre Leon Berard
NETRIS Pharma

Recruiting

Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] (AML-NET)

Acute Myeloid Leukemia Refractory

France
Servier Affaires Médicales

Recruiting

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Acute Myeloid Leukemia (AML)

Netherlands, Italy, Austria, France
Moleculin Biotech, Inc.

Recruiting

Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

Italy, Poland
PETHEMA Foundation

Recruiting

Molecular Diagnostic Platform for AML

Acute Myeloid Leukemia (AML)

Spain
Federal Research Institute of Pediatric Hematology...
Physicians, Innovations, Science for Children Fund

Recruiting

A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML

Acute Myeloid Leukemia, Childhood

Russian Federation
Takeda

Active, not recruiting

A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy (PEVENAZA)

Acute Myeloid Leukemia (AML)

United States, France, Italy, Poland, Canada
University of Ulm

Completed

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)

Acute Myeloid Leukemia (AML)

Germany, Austria
AbbVie

Active, not recruiting

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Acute Myeloid Leukemia (AML)

United States, Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, France, Germany, Greece, Hungary, Ireland, Japan, Korea, Republic of, Mexico, New Zealand, Norway, Puerto Rico, Russian Federation, South Africa, Spain, T... and more
Daiichi Sankyo Co., Ltd.

Completed

Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

China
AbbVie
Sumitomo Pharma Oncology, Inc.

Completed

A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)

United States, Germany, United Kingdom
Astellas Pharma Global Development, Inc.

Completed

Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review

Acute Myeloid Leukemia (AML)

United States

Clinical Trials on Recurrent Acute Myeloid Leukemia, Adult

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations